Acadia Pharmaceuticals price target raised to $28 from $25 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Acadia Pharmaceuticals to $28 from $25 and keeps a Buy rating on the shares following FDA approval of trofinetide with a "clean" label. A broad and clean label provides more upside than was previously valued into Daybue by the Street, positively impacting Daybue launch dynamics, the analyst tells investors in a research note.